What Is NAD+? Benefits, Research & Safety
An essential coenzyme involved in cellular energy production and DNA repair, central to ageing research and available as IV infusions and oral precursor supplements.
UK summary: Not a peptide — a coenzyme. NMN and NR oral precursors are sold as supplements. NAD+ IV drip clinics are popular in the UK; clinical evidence for the marketed wellness outcomes is modest, and pricing is high (£200-500+ per drip).
Quick Facts
Overview
NAD+ — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
Not a peptide — a coenzyme. NMN and NR oral precursors are sold as supplements. NAD+ IV drip clinics are popular in the UK; clinical evidence for the marketed wellness outcomes is modest, and pricing is high (£200-500+ per drip).
02Human evidence grade
03Preclinical evidence grade
04Regulatory status
- UK: NAD+ precursors (NMN, NR) are available as food supplements. IV NAD+ available at private clinics (not NHS-funded).
- EU: NR is available as a supplement. NMN regulatory status varies by country—classified as Novel Food in some jurisdictions.
- Notes: NAD+ and its precursors are not classified as medicines. IV NAD+ therapy is available privately but not evidence-based by NHS standards. NMN was briefly under FDA scrutiny in the US but remains available as a supplement. The field is rapidly evolving with ongoing clinical trials.
05Approved medical uses
None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)
06Unapproved / promotional claims
- Reverses biological ageing.
- Treats long COVID.
- Cures chronic fatigue.
07Common internet claims
- Marketed by IV-drip clinics at £200-500+ per infusion.
- NMN / NR supplements widely sold as longevity precursors.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Reverses biological ageing” | E | No | High | Animal studies show NAD restoration affects ageing-related markers; human ageing-reversal claims are not supported. |
| “IV drips are more effective than oral NMN” | D | Limited | Moderate | IV NAD+ raises blood NAD acutely; whether this drives the wellness outcomes claimed is not established. Oral NMN/NR is far cheaper for sustained elevation. |
| “Safe long-term” | C | Limited | Moderate | Short-term safety data are encouraging; long-term (5+ years) human safety is not established. |
09Safety uncertainty score
Safety profile partly characterised; some signals from observational or preclinical data.
10Known adverse signals
- IV NAD+: flushing, nausea, chest pressure during infusion.
- Theoretical cancer-pathway concerns with sustained NAD+ elevation (mixed signal).
- Sterility issues with grey-market IV preparations.
11Drug-interaction uncertainty
Some interaction data published; check with a prescriber for your specific medicines.
12Anti-doping status
13UK legal position
NAD+ precursors (NMN, NR) are available as food supplements. IV NAD+ available at private clinics (not NHS-funded).
14EU legal position
NR is available as a supplement. NMN regulatory status varies by country—classified as Novel Food in some jurisdictions.
15What this page cannot tell you
- Whether IV NAD+ produces any longevity / wellness benefit beyond the placebo and infusion-experience effect.
- Long-term safety of sustained pharmacological NAD+ elevation.
16Last reviewed
17Citation quality score
18Research gaps
- Phase 3 longevity / disease-prevention outcome trials absent.
- Oral vs IV comparative-effectiveness for any defined outcome.
19Safer alternatives / established care pathways
- Exercise, sleep, Mediterranean diet — the evidence-based longevity interventions.
- NHS investigation for genuine chronic fatigue / long-COVID concerns.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is there a clinical reason to elevate NAD+ for my specific situation, or is this a wellness experiment?
Discovery & History
Mechanism of Action
Researched Benefits
Based on preclinical and clinical research findings:
- 1Restored mitochondrial function in aged mice (preclinical)
- 2Improved insulin sensitivity and metabolic parameters (animal studies)
- 3Enhanced DNA repair capacity (preclinical)
- 4Cardiovascular protection in animal models
- 5Neuroprotection and cognitive improvement (animal studies)
- 6Safe elevation of blood NAD+ levels in humans (clinical trials of NMN/NR)
- 7Potential exercise performance enhancement (limited human data)
Claim vs Evidence
How popular claims about NAD+ stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Reverses biological ageing” | E | No | High | Animal studies show NAD restoration affects ageing-related markers; human ageing-reversal claims are not supported. |
| “IV drips are more effective than oral NMN” | D | Limited | Moderate | IV NAD+ raises blood NAD acutely; whether this drives the wellness outcomes claimed is not established. Oral NMN/NR is far cheaper for sustained elevation. |
| “Safe long-term” | C | Limited | Moderate | Short-term safety data are encouraging; long-term (5+ years) human safety is not established. |
Theoretical Dosing & Protocols
| Theoretical Dosage | IV NAD+: 250-750mg per infusion. Oral NMN: 250-1000mg daily. Oral NR: 300-1000mg daily. |
| Frequency | IV: weekly to monthly sessions. Oral precursors: daily supplementation. |
| Duration | Ongoing; NAD+ levels decline without continued supplementation |
| Notes | NAD+ IV infusions are available at longevity clinics (expensive, £200-500+ per session). Oral precursors (NMN, NR) are available as food supplements without prescription. Quality varies significantly between products. Long-term human efficacy data for anti-ageing is still limited. |
Administration Routes
Routes studied in research settings (educational only):
- Intravenous infusion (IV NAD+)
- Oral (NMN and NR precursor supplements)
- Sublingual (some NMN formulations)
- Intranasal (experimental)
| Half-Life | Stability |
|---|---|
| NAD+ itself has a half-life of hours in circulation; tissue NAD+ pools are maintained by continuous synthesis | IV NAD+ solutions prepared fresh; NMN/NR supplements stable as dry powder |
Safety Profile & Known Risks
Commonly Reported Side Effects
- IV NAD+: nausea, cramping, chest tightness during infusion
- Flushing and warmth (IV)
- Headache
- Mild GI discomfort with oral precursors
- IV infusions can be uncomfortable (2-4 hour duration)
Rare Risks & Concerns
- Theoretical concern about supporting tumour metabolism
- Interaction with NAD+-dependent drug metabolism
- Limited long-term safety data for high-dose supplementation
- IV complications (standard IV risks)
Contraindications
- Active cancer (theoretical concern about fuelling tumour metabolism)
- Pregnancy and breastfeeding (insufficient safety data)
- Concurrent use of NAD+-affecting medications
UK & EU Regulatory Context
🇬🇧 United Kingdom
NAD+ precursors (NMN, NR) are available as food supplements. IV NAD+ available at private clinics (not NHS-funded).
🇪🇺 European Union
NR is available as a supplement. NMN regulatory status varies by country—classified as Novel Food in some jurisdictions.
Clinical Studies Summary
Are manual therapies, passive physical modalities, or acupuncture effective for the management of patients with whiplash-associated disorders or neck pain and associated disorders? An update of the Bone and Joint Decade Task Force on Neck Pain and Its Associated Disorders by the OPTIMa collaboration.
Our review adds new evidence to the Neck Pain Task Force and suggests that mobilization, manipulation, and clinical massage are effective interventions for the management of neck pain.
NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence.
Overall, NAD⁺ augmentation shows clear biological activity, but clinical effectiveness for anti-aging or wellness outcomes remains inconclusive. Larger, well-designed randomized trials with longer follow-up and prespecified clinically meaningful endpoints are needed, particularly for parenteral approaches.
Evaluation of safety and effectiveness of NAD in different clinical conditions: a systematic review.
NADH supplementation is safe and has a low incidence of side effects. Future investigations are needed to evidence the clinical benefits regarding specific diseases and doses administered.
A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment.
Orr has a patent biosignature and therapeutic approach for neuronal senescence pending outside the scope of this work. No other co-authors have COIs to declare.
Effect of nicotinamide riboside on airway inflammation in COPD: a randomized, placebo-controlled trial.
Are employees of Elysium Health and own shares in the company. The other authors declare no competing interests.
The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial.
This trial was registered with ClinicalTrials. gov, NCT04823260, and Clinical Trial Registry - India, CTRI/2021/03/032421.
Registered Trials & Regulatory Status
10 of 13 completed trials have never posted results. Unreported trials are not neutral: results that go unpublished are more often negative ones.
NAD Augmentation to Prevent or Reverse Alzheimer's Disease in People With Down Syndrome
Status: Not Yet Recruiting · 24 participants · Brigham and Women's Hospital
Conditions: Down Syndrome (DS)
To Observe the Clinical Effect of Femoral Nerve Block With Low Concentration of Ropivacaine Based on DPN Grading
Status: Not Yet Recruiting · 60 participants · Zheng Guo
Conditions: Diabetes Mellitus, Type 2
Comparisons of NAD Precursors for Neuroenhancement in Glaucoma Patients
Status: Recruiting · 138 participants · Christopher Kai Shun Leung
Conditions: Glaucoma
Tracing the Metabolic Flux of Orally Administered NAD+ Precursors
Status: Recruiting · 32 participants · Metro International Biotech, LLC
Conditions: Healthy Adults
The NAD-HD Study: A Study to Investigate Efficacy and Safety of Nicotinamide Riboside Compared With Placebo in Huntington's Disease
Status: Recruiting · 120 participants · Oslo University Hospital
Conditions: Huntington Disease
Evaluation of the Impact of an Alteration of NAD+ Metabolism on the Renal Prognosis of Patients Admitted to Intensive Care (NI-AKI)
Status: Recruiting · 150 participants · Ramsay Générale de Santé
Conditions: Acute Renal Insufficiency, NAD
Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)
Status: Active Not Recruiting · 455 participants · Vertex Pharmaceuticals Incorporated
Conditions: Diabetic Peripheral Neuropathic Pain
Nicotinamide Adenine Dinucleotide (NAD+) Metabolism in Human Brown Adipose Tissue
Status: Recruiting · 68 participants · University of Turku
Conditions: Obesity, Abdominal
Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+
Status: Recruiting · 70 participants · Nutraceuticals Research Institute
Conditions: Healthy Aging
Different Amounts of Moxibustion in the Treatment of DPN: A Clinical RCT Study
Status: Active Not Recruiting · 90 participants · Zhejiang Chinese Medical University
Conditions: Diabetic Peripheral Neuropathy, Pain, Moxibustion
Effectiveness of Qualia NAD+ Supplementation on Intracellular NAD Levels
Status: Recruiting · 200 participants · Qualia Life Sciences
Conditions: NAD+ Levels in the Blood
Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus
Status: Recruiting · 78 participants · National Heart, Lung, and Blood Institute (NHLBI)
Conditions: Systemic Lupus Erythematosus (Sle)
Adverse event reports (FDA FAERS)
- fatigue8
- headache6
- insomnia5
- nausea5
- anxiety4
- asthenia3
- cough3
- covid-193
- dizziness3
- palpitations3
FDA FAERS spontaneous reports. A report is not proof the substance caused the event, and an absence of reports is not evidence of safety.
Source: ClinicalTrials.gov and openFDA. Updated automatically.
Looking for NAD+?
Source research-grade NAD+ from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about NAD+
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is there a clinical reason to elevate NAD+ for my specific situation, or is this a wellness experiment?
UK regulatory & safety context
Related Research Guides
Related Peptides
Epitalon
A synthetic tetrapeptide based on epithalamin, researched for its potential effects on telomerase activation and biological ageing.
Learn moreMOTS-c
A mitochondrial-derived peptide that regulates metabolic homeostasis and exercise adaptations, representing a novel class of signalling molecules.
Learn moreHumanin
A mitochondrial-derived peptide with cytoprotective and anti-apoptotic properties, researched for neuroprotection, metabolic regulation, and ageing.
Learn moreSS-31
A mitochondria-targeted tetrapeptide in clinical trials for heart failure, mitochondrial myopathy, and age-related mitochondrial dysfunction.
Learn more